The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pulmonary Arterial Hypertension (PAH)-Global Market Insights and Sales Trends 2024
Synopsis
The global Pulmonary Arterial Hypertension (PAH) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Pulmonary Arterial Hypertension (PAH) market. Prostacyclin and Prostacyclin Analogs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SGC Stimulators segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Pulmonary Arterial Hypertension (PAH) market, driven by demand from China, the second largest economy with some signs of stabilising, the Pulmonary Arterial Hypertension (PAH) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pulmonary Arterial Hypertension (PAH), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pulmonary Arterial Hypertension (PAH) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pulmonary Arterial Hypertension (PAH) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pulmonary Arterial Hypertension (PAH) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pulmonary Arterial Hypertension (PAH) covered in this report include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc.
The global Pulmonary Arterial Hypertension (PAH) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
Global Pulmonary Arterial Hypertension (PAH) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pulmonary Arterial Hypertension (PAH) market, Segment by Type:
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Global Pulmonary Arterial Hypertension (PAH) market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pulmonary Arterial Hypertension (PAH) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Pulmonary Arterial Hypertension (PAH) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Pulmonary Arterial Hypertension (PAH) market. Prostacyclin and Prostacyclin Analogs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SGC Stimulators segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Pulmonary Arterial Hypertension (PAH) market, driven by demand from China, the second largest economy with some signs of stabilising, the Pulmonary Arterial Hypertension (PAH) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pulmonary Arterial Hypertension (PAH), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pulmonary Arterial Hypertension (PAH) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pulmonary Arterial Hypertension (PAH) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pulmonary Arterial Hypertension (PAH) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pulmonary Arterial Hypertension (PAH) covered in this report include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc.
The global Pulmonary Arterial Hypertension (PAH) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
Global Pulmonary Arterial Hypertension (PAH) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pulmonary Arterial Hypertension (PAH) market, Segment by Type:
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Global Pulmonary Arterial Hypertension (PAH) market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pulmonary Arterial Hypertension (PAH) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Pulmonary Arterial Hypertension (PAH)
1.1 Pulmonary Arterial Hypertension (PAH) Market Overview
1.1.1 Pulmonary Arterial Hypertension (PAH) Product Scope
1.1.2 Pulmonary Arterial Hypertension (PAH) Market Status and Outlook
1.2 Global Pulmonary Arterial Hypertension (PAH) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2029)
1.4 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Region (2018-2023)
1.5 Global Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
1.6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
1.6.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
1.6.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
1.6.4 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
1.6.5 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
2 Pulmonary Arterial Hypertension (PAH) Market by Type
2.1 Introduction
2.1.1 Prostacyclin and Prostacyclin Analogs
2.1.2 SGC Stimulators
2.1.3 ERA
2.1.4 PDE-5
2.2 Global Pulmonary Arterial Hypertension (PAH) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2018-2023)
2.2.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
3 Pulmonary Arterial Hypertension (PAH) Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.2 Global Pulmonary Arterial Hypertension (PAH) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2018-2023)
3.2.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
4 Pulmonary Arterial Hypertension (PAH) Competition Analysis by Players
4.1 Global Pulmonary Arterial Hypertension (PAH) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2022)
4.3 Date of Key Players Enter into Pulmonary Arterial Hypertension (PAH) Market
4.4 Global Top Players Pulmonary Arterial Hypertension (PAH) Headquarters and Area Served
4.5 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
4.6 Competitive Status
4.6.1 Pulmonary Arterial Hypertension (PAH) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Actelion
5.1.1 Actelion Profile
5.1.2 Actelion Main Business
5.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
5.1.4 Actelion Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
5.1.5 Actelion Recent Developments
5.2 Gilead Sciences
5.2.1 Gilead Sciences Profile
5.2.2 Gilead Sciences Main Business
5.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
5.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
5.2.5 Gilead Sciences Recent Developments
5.3 United Therapeutics
5.3.1 United Therapeutics Profile
5.3.2 United Therapeutics Main Business
5.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
5.3.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
5.3.5 GlaxoSmithKline Recent Developments
5.4 GlaxoSmithKline
5.4.1 GlaxoSmithKline Profile
5.4.2 GlaxoSmithKline Main Business
5.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
5.4.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
5.4.5 GlaxoSmithKline Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
5.5.4 Pfizer Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Bayer
5.6.1 Bayer Profile
5.6.2 Bayer Main Business
5.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
5.6.4 Bayer Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
5.6.5 Bayer Recent Developments
5.7 Arena
5.7.1 Arena Profile
5.7.2 Arena Main Business
5.7.3 Arena Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
5.7.4 Arena Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
5.7.5 Arena Recent Developments
6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pulmonary Arterial Hypertension (PAH) Market Dynamics
11.1 Pulmonary Arterial Hypertension (PAH) Industry Trends
11.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
11.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
11.4 Pulmonary Arterial Hypertension (PAH) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
